The Severance Hospital of the Yonsei University
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rha, Sunyoung
NCT04640480: Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

Not yet recruiting
1
36
RoW
SNB-101, SN-38
SN BioScience
Colorectal Cancer, Breast Cancer, Pancreas Cancer, Ovarian Cancer, Small-cell Lung Cancer, Gastric Cancer, Head and Neck Cancer
12/24
06/25
ABL103-1001, NCT06126666: A Study with ABL103 in Subjects with Advanced or Metastatic Solid Tumors

Recruiting
1
96
RoW
ABL103
ABL Bio, Inc.
Advanced Solid Tumor
06/25
11/27
NCT05101109: Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

Completed
1
24
RoW
ABL501, Bispecific antibody for LAG-3 and PD-L1
ABL Bio, Inc.
Advanced Solid Tumor
05/24
05/24

Download Options